Recent Updates
Recently added Catalysts
LUCD Positive Sentiment Score: 70/100

Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026

Key Takeaway: Lucid Diagnostics Inc. will hold a business update conference call on May 14, 2026, at 8:30 AM ET. CEO Lishan Aklog will discuss the company's operations and growth strategy, while CFO Dennis McGrath will present the first quarter 2026 financial results. The call will be accessible via webcast and telephone.

Market Sentiment Analysis

POSITIVE FACTORS

  • Lucid Diagnostics is hosting a business update conference call.
  • The company is focused on cancer prevention through innovative diagnostics.
  • The EsoGuard® test aims to improve early detection of esophageal precancer.

Full Press Release Details

Conference Call and Webcast at 8:30 AM ET
NEW YORK,April 30, 2026/PRNewswire/ --Lucid Diagnostics Inc.(Nasdaq:LUCD)("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq:PAVM), today announced that it will host a business update conference call and webcast on Thursday, May 14, 2026, at 8:30 AM ET. During the call,Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition,Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's first quarter 2026 financial results.
The webcast will be available at the investor relations section of the Company's website atluciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website atluciddx.com.
About Lucid DiagnosticsLucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq:PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid'sEsoGuard®Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with itsEsoCheck®Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information, please visitwww.luciddx.comand for more information about its parent company PAVmed, please visitwww.pavmed.com.
SOURCE Lucid Diagnostics

21%

Frequently Asked Questions

When is the Lucid Diagnostics business update call?

The business update call is scheduled for May 14, 2026, at 8:30 AM ET.

Who will present during the conference call?

CEO Lishan Aklog and CFO Dennis McGrath will present during the call.

How can I access the conference call?

Listeners can join via webcast or by calling specific phone numbers provided.

What is the focus of Lucid Diagnostics?

Lucid Diagnostics focuses on cancer prevention, particularly for patients at risk of esophageal cancer.

Last updated: Apr 30, 2026